BACKGROUND Adalimumab (ADA) and infliximab (IFX) are the cornerstones of the
treatment of Crohn's disease (CD). It remains controversial whether there is a difference in …

Background Few data are currently available about SB5 in inflammatory bowel diseases
(IBD). The aim of this study was to assess the effectiveness and safety of SB5 in a cohort of …

Objective This study aimed to review effectiveness studies comparing two biological anti-
tumour necrosis factor agents, adalimumab (ADA) and infliximab (IFX), in the management …

Background Conventional therapy of inflammatory bowel disease with traditional
immunosuppressant medication is increasingly being replaced by biological agents …

METHODS: Among 100 patients, 75 met the inclusion criteria, and 62 were matched by
propensity score. We evaluated time to treatment escalation as the primary outcome and …

OBJECTIVE: Long-term comparison studies between infliximab (IFX) and adalimumab
(ADA) with or without immunomodulator therapy are still needed in Crohn's disease (CD). In …

Abstract Background and Aim Although previous studies compared the efficacy of infliximab
(IFX) versus adalimumab (ADA) as the first‐line biologics for Crohn's disease (CD), the …

This was a 1-year prospective observational study of the health-related quality of life
(HRQoL) of moderate to severe crohn's disease (CD) patients in Iran. Patients' HRQoL were …

Purpose There is currently no curative treatment for childhood Crohn's disease (CD). This
meta-analysis aimed to validate the efficacy and safety of adalimumab (ADA) in pediatric …

Since their introduction almost 20 years ago, anti-tumor necrosis factor agents (anti-TNFs)
have revolutionized Crohn's disease (CD) management. Despite the availability of newer …